SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-018371
Filing Date
2023-03-08
Accepted
2023-03-08 08:10:17
Documents
14
Period of Report
2023-03-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea174762-8k_protara.htm   iXBRL 8-K 34242
2 PRESS RELEASE DATED MARCH 8, 2023, ISSUED BY THE REGISTRANT ea174762ex99-1_protara.htm EX-99.1 97293
6 GRAPHIC ex99-1_001.jpg GRAPHIC 2504
  Complete submission text file 0001213900-23-018371.txt   321416

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE tara-20230308.xsd EX-101.SCH 3230
4 XBRL LABEL FILE tara-20230308_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE tara-20230308_pre.xml EX-101.PRE 22361
8 EXTRACTED XBRL INSTANCE DOCUMENT ea174762-8k_protara_htm.xml XML 3627
Mailing Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010 646-844-0337
Protara Therapeutics, Inc. (Filer) CIK: 0001359931 (see all company filings)

IRS No.: 204580525 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36694 | Film No.: 23714909
SIC: 2836 Biological Products, (No Diagnostic Substances)